1
|
Xu H, Fan L, Luo H, Ju X, Li H, Rong S, Yuan Y, Xiao J, Zhang R, Wang K, Zou R, Hao F, Shi Y, Zhou Y, Yang Z, Liu Y, Gong B. Genetic association of MIR-449B, GCLC, eNOS, SORD, and ENPP1 with diabetic retinopathy. Exp Eye Res 2025; 253:110287. [PMID: 39952424 DOI: 10.1016/j.exer.2025.110287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Revised: 11/09/2024] [Accepted: 02/11/2025] [Indexed: 02/17/2025]
Abstract
Identifying the genetic risk factors of diabetic retinopathy (DR) is essential for discovering the potential pathogenesis of DR. This study determined the association of DR with five single nucleotide polymorphisms (SNPs) specifically in type 2 diabetes mellitus (T2DM) patients, including rs10061133(MIR-449B), rs17883901(GCLC), rs2070744(eNOS), rs3759890 (SORD) and rs7754561 (ENPP1). A total of 1433 individuals were enrolled in this study, comprising healthy controls (ctrls = 480), individuals with diabetes mellitus without retinopathy (DNR = 480), non-proliferative DR(NPDR = 378), and proliferative DR(PDR = 95). The five SNPs were genotyped utilizing Mass ARRAY MALDI-TOF technology. Odds ratio (OR) and 95% confidence intervals (95% CI) were calculated for the risk of genotype and allele. We performed a literature search in PubMed published before July 16, 2023. The Newcastle Ottawa Scale was used to evaluate the overall quality of the case-control studies. Consequently, we found that there were statistically significant differences between PDR cases and healthy controls for rs10061133 (P = 0.007, OR = 1.59, 95% CI = 1.32-2.23) and rs17883901 (P = 0.020, OR = 1.67, 95% CI = 1.08-2.57), rs17883901 was significantly associated with NPDR (P = 0.023, OR = 1.39, 95% CI = 1.05-1.85), there was a significant association between DR cases and healthy controls (P = 0.048, OR = 1.22, 95% CI = 1.00-1.48) for rs3759890 in the allelic model. DR show no relationships with the other two SNPs compared to healthy controls. In multivariate analyses comparing the DR and DNR groups, rs7754561(A), rs10061133(G), and rs17883901(A) were identified as risk loci for DR in individuals with a duration of diabetes of ≥5 years (P = 0.0023, P = 0.0037, and P = 0.0376, respectively). Furthermore, individuals carrying rs10061133(G) exhibited a higher risk of DR in the hyperglycemic group (glucose ≥8 mmol/L). Secondly, we showed that one polymorphism in eNOS (rs2070744, T > C) showed a suggestive association with DR in the meta-analysis (allelic model:P < 0.05, OR = 1.18, 95% CI: 1.07-1.30, Z = 3.46, I2 = 34%). Subsequently, including studies that used either healthy subjects or diabetic subjects without DR as controls, the association of eNOS rs2070744 with DR was consistently significant (P = 0.002) and exhibited intermediate heterogeneity (I2 = 48%). Furthermore, polymorphisms in GCLC (rs17883901) and SORD (rs3759890) were also associated with DR, with P-values of 0.004 (I2 = 93%) and 0.03 (I2 = 3%), respectively, suggesting their potential involvement in the disease. In conclusion, this study documented that rs10061133(G), rs17883901(A), and rs3759890(G) could be the independent risk factors for retinopathy in Chinese patients with T2DM, offering a foundation for genetic risk assessment in clinical practice. Furthermore, our meta-analysis reveals a significant association between rs2070744 and DR, implying the potential involvement of the MIR-449B, GCLC, SORD, and eNOS variants in the development of DR, which could be a promising direction for developing new treatments aimed at mitigating the risk of DR in susceptible populations.
Collapse
Affiliation(s)
- Huijuan Xu
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
| | - Lin Fan
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China; Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China; The University of Chinese Academy of Sciences, Beijing, China
| | - Huaichao Luo
- Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
| | - Xueming Ju
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Huan Li
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
| | - Shisong Rong
- Department of Ophthalmology, Mass Eye and Ear, Mass General Brigham, Harvard Medical School, USA
| | - Ye Yuan
- Department of Clinical Laboratory, Qionglai Medical Center Hospital, Sichuan, China
| | - Jialing Xiao
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Ruifan Zhang
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Kaifang Wang
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Rong Zou
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Fang Hao
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Yi Shi
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Yu Zhou
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
| | - Zhenglin Yang
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China; Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China; The University of Chinese Academy of Sciences, Beijing, China; Jinfeng Laboratory, Chongqing, China
| | - Yijun Liu
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
| | - Bo Gong
- The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China.
| |
Collapse
|
2
|
Isaiev O, Serdiuk V, Ziablitsev D. PREDICTING THE OCCURRENCE OF PRIMARY OPEN-ANGLE GLAUCOMA DEPENDING ON THE GENETIC POLYMORPHISM ENDOTHELIAL NO SYNTHASE (NOS3) GENE. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2023; 75:3087-3093. [PMID: 36723332 DOI: 10.36740/wlek202212133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE The aim: To develop the model for predicting primary open - angle glaucoma (POAG) depending on the presence of the genetic polymorphism in the endothelial NO-synthase (NOS3) gene. PATIENTS AND METHODS Materials and methods: The results of genotyping 153 patients (153 eyes) with POAG are included in this investigation. 47 patients were in the control group. Their age was 65,0±13,1 years, duration of disease - 4,9±5,3 years. The polymerase chain reaction was carried out in the patients' blood in the real time mode (Gene Amp® PCR System 7500 amplifier; USA) with the help of the TaqMan Mutation Detection Assays Life-Technology test system (USA). The program Statistica 10 (StatSoft, Inc., USA) was used for mathematical testing of the obtained results. RESULTS Results: The regression analysis confirmed the effect of rs1799983 and rs2070744 polymorphisms of the NOS3 gene on the development of POAG. Calculating their specific gravity based on the degree of the impact on the probability of developing the disease showed that rs2070744 - 72.2% had the greater impact than rs1799983 - 38.5%. The regression model of POAG risk depending on the genotypes of the NOS3 gene rs1799983 and rs2070744 polymorphisms was constructed with the satisfactory quality of mathematical prediction (-2log=202.59; χ2=28.91; P<0.001). The value of probability of developing POAG exceeded the limit value (Cut-off=0.8), respectively, OR 4.39 (95% CI 1.00-19.30; P=0.048) and OR 14.15 (95% CI 1.88-106.28; P<0.001) in carriers of the rs1799983 and rs2070744 GT-CC and TT-CC haplotypes. CONCLUSION Conclusions: The results of the study proved the importance of risk genotypes (TT rs1799983 and CC rs 2070744) for the development of POAG in patients from the Ukrainian population. It has been shown that the significant increase in the risk of POAG exists for carriers of the GT-CC and TT-CC haplotypes.
Collapse
|
3
|
Liu Y, Li Z, Gao R, Wang W, Cao T, Ma S. Acupuncture treatment of glaucoma based on radar plots: A protocol for an overview of systematic reviews. Medicine (Baltimore) 2021; 100:e27261. [PMID: 34559130 PMCID: PMC8462583 DOI: 10.1097/md.0000000000027261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Accepted: 08/31/2021] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Glaucoma is the second most blinding eye disease in the world. Currently, lowering the intraocular pressure through various methods is the main treatment of glaucoma. Acupuncture has been effectively and safely used in the treatment of glaucoma. However, the evidence for the efficacy of acupuncture in the treatment of glaucoma is controversial, leading to inconsistent findings from systematic evaluations at abroad and home. Therefore, this protocol aims to provide a multivariate evaluation on the quality of evidences from current systematic reviews (SRs) and/or meta-analyzes (MAs) of acupuncture in the treatment of glaucoma, and literature quality, thus providing an intuitive and reliable evidence synthesis and basis for clinical decision making. METHODS MAs/SRs about the acupuncture treatment of glaucoma will be searched online, including Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), Web of Science, Embase, PubMed, and Cochrane Library. Two investigators will independently screen literatures according to inclusion and exclusion criteria and extract data. A multivariate evaluation of the included literature will be performed by depicting radar plots in 6 aspects as follows: Year of publication, study type, SRs assessment through the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2), literature quality assessment through the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), homogeneity, and publication bias. The Grading of Recommendations Assessment, Development, and Evaluation evidence quality assessment tool will be used to grade and evaluate the quality of outcome indicators of the included literatures. RESULTS This study will be submitted for publication in a peer-reviewed journal. CONCLUSION We would like to provide a visual and scientific approach for clinical decision making of acupuncture treatment of glaucoma through a accessible and useful assessment of systematic reviews.
Collapse
Affiliation(s)
- Yu Liu
- Department of Ophthalmology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China
| | - Zhangxin Li
- Department of Ophthalmology, Qinghai Red Cross Hospital, Xining, Qinghai Province, China
| | - Ruixin Gao
- Department of Ophthalmology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China
| | - Wei Wang
- Department of Ophthalmology, Kunming Municipal Hospital of Traditioal Chinese Medicine, Kunming, Yunnan Province, China
| | - Tingting Cao
- Department of Ophthalmology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China
| | - Suhong Ma
- College of Acupuncture, Massage and Rehabilitation, Yunnan University of Chinese Medicine, Kunming, Yunnan Province, China
| |
Collapse
|